BioCardia, Inc. Cash Flow Statement
BCDA|3 years of annual SEC 10-K data (FY2011-FY2017)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$9M
FY2017
Free Cash Flow
-$9M
FY2017
Capital Expenditures
$136,000
Cash used for long-term assets
Dividends Paid
N/A
FY2017
BioCardia, Inc. used $9M in operating cash flow and negative free cash flow of $9M in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.83 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -110.6% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 | FY2011 |
|---|---|---|---|
| Net Income | -$12.3M | -$10.3M | $9.7M |
| Depreciation & Amortization | $78.0K | $39.0K | $0 |
| Operating Cash Flow | -$8.7M | -$5.5M | -$3.1M |
| Capital Expenditures | $136.0K | - | $137.0K |
| Free Cash Flow | -$8.8M | - | -$3.2M |
| FCF Margin | -1838.6% | - | -26866.7% |